Martin Shkreli

As Nvidia Corp. (NASDAQ:NVDA) turned the most valuable publicly traded company on Thursday, inching closer to a $4 trillion market capitalization, this multinational technology company, nicknamed ‘Big Blue,’ has outperformed the Magnificent 7 and the Jensen Huang-led tech giant in 2025...

Many big tech companies, including startups, are foraying into the emerging field of quantum computing. Out of the 300 quantum computing patents issued in 2025, two companies have received the most. What Happened: International Business Machines Corp. and Alphabet Inc.‘s (NASDAQ:GOOGL) Google...

On Monday, Cathie Wood-led Ark Invest made significant trades, notably offloading shares of Tesla Inc. (NASDAQ:TSLA) and Palantir Technologies Inc. (NASDAQ:PLTR). The Tesla Trade: Ark Invest sold 1,594 shares of the Elon Musk-led company. For the day, Tesla shares closed at $342.69, making the...

Former hedge fund manager Martin Shkreli expressed bullish views on Palantir Technologies Inc. (NASDAQ:PLTR) while cautioning investors about the stock’s inherent volatility during an interview with popular PLTR investor Amit Kukreja. What Happened: Shkreli, popularly known as "Pharma Bro,"...

Former hedge fund manager Martin Shkreli took aim at the quantum computing industry again on Monday, posting a series of critical remarks on X. What Happened: Shkreli, widely known as “Pharma Bro” for his controversial role in the pharmaceutical industry, dismissed the commercial...

Martin Shkreli, the controversial former hedge fund manager known as “Pharma Bro,” questioned but ultimately defended Palantir Technologies Inc.‘s (NYSE:PLTR) growth projections on Wednesday, calling analysis of the company’s $4 million average revenue per customer “...

As the Chairman and CEO of Microsoft Corp. (NASDAQ:MSFT), Satya Nadella announced the world's first-of-a-kind quantum chip – Majorana 1, quantum computing stocks jumped with the euphoria surrounding the discovery. What Happened: Even as skeptics raised questions on the usage of the word "...

Former hedge fund manager Martin Shkreli cast doubt on recent quantum computing advances and stock valuations, particularly targeting IonQ Inc. (NYSE:IONQ) and Rigetti Computing Inc. (NASDAQ:RGTI) in a series of posts on X on Wednesday. What Happened: “IONQ and RGTI are both worth low single...

Martin Shkreli, the former hedge fund manager known as “Pharma Bro,” defended Palantir Technologies Inc.‘s (NYSE:PLTR) valuation on Tuesday amid the company’s surging stock price, projecting substantial cash flow growth for the data analytics firm through 2025. What Happened...

Former hedge fund manager Martin Shkreli called quantum computing stocks IonQ Inc. (NYSE:IONQ) and Rigetti Computing Inc. (NASDAQ:RGTI) “one of the best shorts” of his career, despite both companies seeing substantial gains in recent trading sessions. What Happened: Shkreli, posting on...

MicroStrategy Inc (NASDAQ:MSTR) is riding the Bitcoin (CRYPTO: BTC) rollercoaster like no other, but the thrill seems to have hit a steep drop. Once the darling of crypto-linked assets in 2024, boasting a jaw-dropping 342% year-to-date gain, the stock is now grappling with a sharp bearish turn....

Controversial figure Martin Shkreli issued a stark warning for Bitcoin (CRYPTO: BTC) proxy stock, MicroStrategy Inc. (NASDAQ:MSTR), on Monday, predicting its potential liquidation and a significant Bitcoin surge. What Happened: Shkreli, popularly known as “Pharma Bro,” took to...

Wall Street witnessed a historic day with the S&P 500 and Dow Jones Industrial Average reaching record highs. The Russell 2000 index also hit an all-time high, driven by easing global geopolitical tensions, post-election bullish momentum, and favorable seasonal trends. However, Bitcoin and Gold...

Cassava Sciences (NASDAQ:SAVA) stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed by the market. Martin Shkreli, a well-know figure in the pharmaceutical space, predicted the stock’s crash...

In a significant legal development, the U.S. Supreme Court has denied Martin Shkreli’s appeal to overturn a $64.6 million repayment order. This decision marks another setback for the former pharmaceutical executive, infamously known as “Pharma Bro.” What Happened: Shkreli’s...